Crinetics Pharmaceuticals, Inc. - Common Stock - fluxo de caixa (NASDAQ:CRNX)

Financials

Fluxo de caixa operacional -62.03 M-88.59 M-115.2 M-166.31 M-225.97 M-377.92 M -414.17 M Fluxo de caixa de investimento 217 K-56.48 M-173.98 M-200.41 M-574.82 M173.91 M 7.51 M Fluxo de caixa de financiamento 114.57 M252.68 M121.96 M388.94 M1.01 B40.61 M 426.05 M Fluxo de caixa livre -62.03 M-88.59 M-115.2 M-166.31 M-225.97 M-383.68 M -419.52 M

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.

CRNX

Financials

Crinetics Pharmaceuticals, Inc. - Common Stock

Notícias

3 Best Healthcare Stocks to Buy in May 2026, According to Analysts - TipRanks.com

Transcrição do resultado: Crinetics Pharma supera previsão de receita no 1º tri 2026

Oppenheimer reduz preço-alvo da Crinetics após receita superar estimativas

Citizens reduz preço-alvo da Crinetics para US$ 95 por avaliação

Crinetics Pharmaceuticals, Inc. (CRNX) Q1 2026 Earnings Call Transcript

Slides do 1º tri 2026 da Crinetics: lançamento do Palsonify impulsiona receita 26% acima do esperado

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates

Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

Citizens eleva preço-alvo das ações da Crinetics após aprovação de medicamento na UE

Crinetics recebe aprovação da UE para medicamento contra acromegalia Palsonify

Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates